SEC For	m 4 FORM	4	UNITED S	STAT	ES	SE		ITIE	ES AND	ЕХСНА	NGE C	оммі	SSION				
						Washington, D.C. 20549									ОМВ	APPRO\	/AL
Section 16. Form 4 or Form 5 obligations may continue. See						JT OF CHANGES IN BENEFICIAL OWNE pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940							SHIP	Estima	OMB Number: 3235-028 Estimated average burden hours per response: 0.		
1. Name and Address of Reporting Person [*] <u>Arthur David J.</u>						2. Issuer Name and Ticker or Trading Symbol Salarius Pharmaceuticals, Inc. [SLRX]							Relationship o eck all applio X Directo	cable)	Reporting Person(s) to Issuer Ile) 10% Owne		
(Last) (First) (Middle) C/O SALARIUS PHARMACEUTICALS, INC. 2450 HOLCOME BLVD., SUITE J-608					3. Date of Earliest Transaction (Month/Day/Year) 03/23/2020								X Officer (give title Other (specify below) Chief Executive Officer				
(Street)					4. If Amendment, Date of Original Filed (Month/Day/Year)								 B. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting 				.
(City)										Person							
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					ar) E	2A. Deemed Execution Date, if any (Month/Day/Yea		Code (Ins				Beneficia Owned F	s For ally (D) ollowing (I) (I		m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code V	Amount	(A) or (D)	Price	rice Reported Transaction (Instr. 3 and				(Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Co	ansaction ode (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exer Expiration D (Month/Day/	ate	7. Title an of Securit Underlyin Derivative (Instr. 3 ar	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactie (Instr. 4)	tive ties cially I ing ted ction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Co	de	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$0.61	03/23/2020		A	4		60,000		(1)	03/22/2030	Common Stock	60,000	\$0	60,000	0	D	

Explanation of Responses:

1. 25% of the options granted are fully vested on March 23, 2021, and quarterly vesting of the remaining options over 3 years.

Remarks:

/s/ David J. Arthur

** Signature of Reporting Person Date

03/25/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.